Reuters logo
BRIEF-Glaxosmithkline says ‍results of first study assessing levels of organ damage in patients with active SLE
November 8, 2017 / 5:33 PM / 14 days ago

BRIEF-Glaxosmithkline says ‍results of first study assessing levels of organ damage in patients with active SLE

Nov 8 (Reuters) - GLAXOSMITHKLINE PLC:

* SAYS ‍RESULTS OF FIRST STUDY ASSESSING LEVELS OF ORGAN DAMAGE IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) TREATED WITH BENLYSTA (BELIMUMAB) PLUS STANDARD OF CARE (SOC) VERSUS SOC ALON​E

* ‍PATIENTS WITH SLE ARE AT RISK OF IRREVERSIBLE ORGAN DAMAGE, WHICH CAN ACCRUE OVER TIME AND IS ASSOCIATED WITH INCREASED RISK OF DEATH​

* ‍SAFETY PROFILE OBSERVED IN BLISS-76 LONG-TERM EXTENSION STUDY WAS CONSISTENT WITH THAT OBSERVED IN OVERALL BLISS CLINICAL TRIAL PROGRAMME FOR BELIMUMAB​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below